Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Inclusion criteria

• Healthy male volunteer in the age of 19-45
• Body weight ≥ 55 kg and in the range of calculated IBW ±20%
• Subject without a hereditary problems, chronic disease and morbid symptom
• Suitable clinical laboratory test values
• Subject who sign on an informed consent form willingly

Exclusion criteria

• Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
• Gastrointestinal disease or gastrointestinal surgery
• History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
• Galactose intolerance
• Sitting systolic blood pressure ≥ 140 mmHg or< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 beats per minute
• Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range
• Serum Creatinine > upper limit of normal range
• Drug abuse
• Subject treated metabolizing enzyme inducers or inhibitors within 1 month
• Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
• Subject treated Investigational product(include Bioequivalence test) within 3 months
• Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
• Continuously taking Alcohol > 21 units/week
• Cigarette > 10 cigarettes/day
• Subjects with planning of dental treatment or any surgery
• Another clinical condition in judgement of investigator